Actively Recruiting

Phase Not Applicable
Age: 18Years - 65Years
All Genders
ID06839079

Feasibility Randomized Trial of an Adapted Virtual Cognitive Rehabilitation Program for Refugees and Asylum Seekers With Traumatic Brain Injury and Cognitive Impairment

Led by Massachusetts General Hospital · Updated on 2026-03-11

50

Participants Needed

1

Research Sites

39 weeks

Total Duration

On this page

Sponsors

M

Massachusetts General Hospital

Lead Sponsor

N

National Institute of Neurological Disorders and Stroke (NINDS)

Collaborating Sponsor

AI-Summary

What this Trial Is About

Researchers are evaluating a cognitive rehabilitation program designed to help refugees and asylum seekers who have experienced traumatic brain injury (TBI) and suffer from cognitive challenges like problems with thinking, learning, concentration, and memory. This study aims to test if the program is practical to use and if participants find it helpful. The trial involves English and Spanish speakers and is conducted by Massachusetts General Hospital using a randomized design. Participants are randomly assigned to one of two groups. One group receives the adapted cognitive rehabilitation program immediately, which includes eight virtual sessions led by a trained bilingual paraprofessional. These sessions teach strategies for managing cognitive symptoms, such as relaxation, attention, memory exercises, and education about TBI and related symptoms like depression and anxiety. The second group serves as a waitlist control, completing assessments before receiving the program approximately 12 weeks later. Both groups complete questionnaires at baseline, 12 weeks, and 24 weeks. During the study, participants complete assessments to measure how acceptable, feasible, and satisfying the program is, along with questionnaires assessing cognitive symptoms and post-concussion effects. The program lasts about eight weeks, and follow-up questionnaires occur at 12 and 24 weeks after starting. Researchers monitor adherence and participant feedback throughout. The trial is open to adults aged 18 to 65 who meet specific criteria and will continue until December 2027.

CONDITIONS

Brief Title

Cognitive Rehabilitation for Refugees With Traumatic Brain Injury and Cognitive Impairment

Who Can Participate

Age: 18Years - 65Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Identify as an asylum seeker, refugee, or have been granted asylum or humanitarian relief
  • Experienced mild or moderate traumatic brain injury after age 18
  • Age between 18 and 65 years
  • Have subjective cognitive impairment
  • Proficient in English or Spanish
  • Able to provide verbal informed consent
  • Willing and able to participate in the intervention and answer questionnaires
Not Eligible

You will not qualify if you...

  • Currently receiving or received cognitive rehabilitation treatment in the past 3 months
  • Severe traumatic brain injury or TBI sustained only before age 18
  • Diagnosis of bipolar disorder, psychosis, active substance use, or current active suicidal thoughts or plans (may be re-screened after 30 days if applicable)

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person or virtual)

Baseline Assessment

Duration - 1 day

Participants complete baseline assessments including target outcomes, demographic and general health information.

1 visit (virtual)

Adapted Cognitive Rehabilitation Program

Duration - Approximately 8 weeks

Participants complete 8 individual virtual sessions with a trained bilingual paraprofessional focused on cognitive rehabilitation to address cognitive symptoms related to traumatic brain injury.

Weekly virtual sessions for 8 weeks

Follow-up Assessments

Duration - Up to 24 weeks after baseline

Participants complete follow-up questionnaires to assess acceptability, feasibility, satisfaction, and potential effectiveness of the intervention at 12 weeks and 24 weeks after baseline.

2 virtual assessments at approximately 12 weeks and 24 weeks after baseline

Trial Site Locations

Total: 1 location

1

Massachusetts General Hospital

Boston, Massachusetts, United States, 02114

Actively Recruiting

Loading map...

Research Team

A

Altaf Saadi, MD

How is the study designed?

Study Type

INTERVENTIONAL

Masking

SINGLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

HEALTH_SERVICES_RESEARCH

Number of Arms

2

Similar Trials

Augmented Renal Clearance in Neurocritical Care Population: ...

TBI (Traumatic Brain Injury)

Actively Recruiting

3 locations

Brain Development in Young Children Following Mild Traumatic...

TBI (Traumatic Brain Injury)

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Published Research Related To This Trial

The Presence and Profile of Neurological Conditions and Associated Psychiatric Comorbidities in U.S. Resettled Refugees: A Retrospective Single Center Study.

A Parvez, S Percac-Lima, A Saadi

https://pubmed.ncbi.nlm.nih.gov/36251204

Research Letter: Assessing Traumatic Brain Injury in Refugees: Feasibility, Usability, and Prevalence Insights From a US-Based Clinical Sample.

Sofia Sherman Rosa, Rodrigo Nadal, Altaf Saadi

https://pubmed.ncbi.nlm.nih.gov/39874279

Head Injury and Associated Sequelae in Individuals Seeking Asylum in the United States: A Retrospective Mixed-Methods Review of Medico-Legal Affidavits.

Altaf Saadi, Julia Asfour, Maria Vassimon De Assis...

https://pubmed.ncbi.nlm.nih.gov/38928599

Clinician perspectives on characteristics and care of traumatic brain injury among asylum seekers and refugees.

Nusrath Jahan, Margarita Velasco, Ana-Maria Vranceanu...

https://pubmed.ncbi.nlm.nih.gov/38831593